This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:
Compares traditional ultrasound with advanced imaging techniques.
Examines AI-based approaches in patient classification.
The episode concludes with a forward-looking perspective on the future management of MASLD.
Faculty
Thomas Berg (Moderator)
Timm Denecke (Faculty)
Juan-Manuel Pericàs (Faculty)
Valérie Vilgrain (Faculty)
This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.
Podden och tillhörande omslagsbild på den här sidan tillhör European Association for the Study of the Liver. Innehållet i podden är skapat av European Association for the Study of the Liver och inte av, eller tillsammans med, Poddtoppen.
